SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-038530
Filing Date
2023-05-11
Accepted
2023-05-11 16:06:31
Documents
56
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0323_tffpharma.htm   iXBRL 10-Q 603132
2 CERTIFICATION f10q0323ex31-1_tffpharma.htm EX-31.1 10314
3 CERTIFICATION f10q0323ex31-2_tffpharma.htm EX-31.2 10341
4 CERTIFICATION f10q0323ex32-1_tffpharma.htm EX-32.1 7724
5 GRAPHIC image_001.jpg GRAPHIC 2933
  Complete submission text file 0001213900-23-038530.txt   3256499

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20230331.xsd EX-101.SCH 50110
7 XBRL CALCULATION FILE tffp-20230331_cal.xml EX-101.CAL 27037
8 XBRL DEFINITION FILE tffp-20230331_def.xml EX-101.DEF 163803
9 XBRL LABEL FILE tffp-20230331_lab.xml EX-101.LAB 353770
10 XBRL PRESENTATION FILE tffp-20230331_pre.xml EX-101.PRE 176569
50 EXTRACTED XBRL INSTANCE DOCUMENT f10q0323_tffpharma_htm.xml XML 250755
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 23910969
SIC: 2834 Pharmaceutical Preparations